Your browser doesn't support javascript.
loading
Role of receptor occupancy assays by flow cytometry in drug development.
Stewart, Jennifer J; Green, Cherie L; Jones, Nicholas; Liang, Meina; Xu, Yuanxin; Wilkins, Danice E C; Moulard, Maxime; Czechowska, Kamila; Lanham, David; McCloskey, Thomas W; Ferbas, John; van der Strate, Barry W A; Högerkorp, Carl-Magnus; Wyant, Timothy; Lackey, Alan; Litwin, Virginia.
Afiliación
  • Stewart JJ; Flow Contract Site Laboratory, LLC, Bothell, Washington, 98012.
  • Green CL; Amgen, Inc, Thousand Oaks, California, 91320.
  • Jones N; LabCorp Clinical Trials, Laboratory Corporation of America® Holdings, Brentwood, Tennessee, 37027.
  • Liang M; Medimmune, LLC, Mountain View, California, 94043.
  • Xu Y; Alnylam Pharmaceuticals, Cambridge, Massachusetts, 02142.
  • Wilkins DE; Charles River Laboratories International, Inc, Reno, Nevada, 89511.
  • Moulard M; BioCytex, Marseille, 13010, France.
  • Czechowska K; Covance Central Laboratory Services, Geneva, 1217, Switzerland.
  • Lanham D; Eurofins Pharma Bioanalysis Services UK Limited, Park Abingdon, OX14 4RY, United Kingdom.
  • McCloskey TW; ICON Laboratory Services, Farmingdale, New York, 11735.
  • Ferbas J; Amgen, Inc, Thousand Oaks, California, 91320.
  • van der Strate BW; PRA Healthsciences, Assen, TK, 9407, The Netherlands.
  • Högerkorp CM; Xintela AB, Lund, SE-223 81, Sweden.
  • Wyant T; Takeda Pharmaceuticals, Cambridge, Massachusetts, 02139.
  • Lackey A; LabCorp Clinical Trials, Laboratory Corporation of America® Holdings, Brentwood, Tennessee, 37027.
  • Litwin V; Covance Central Laboratory Services, Indianapolis, Indiana, 46214.
Cytometry B Clin Cytom ; 90(2): 110-6, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26704557
ABSTRACT
The measurement of the binding of a biotherapeutic to its cellular target, receptor occupancy (RO), is increasingly important in development of biologically-based therapeutic agents. Receptor occupancy (RO) assays by flow cytometry describe the qualitative and/or quantitative assessment of the binding of a therapeutic agent to its cell surface target. Such RO assays can be as simple as measuring the number of cell surface receptors bound by an antireceptor therapeutic agent or can be designed to address more complicated scenarios such as internalization or shedding events once a receptor engages the administered therapeutic agent. Data generated from RO assays can also be used to model whether given doses of an experimental therapeutic agent and their administration schedules lead to predicted levels of receptor occupancy and whether the receptor is modulated (up or down) on cells engaged by the therapeutic agent. There are a variety of approaches that can be used when undertaking RO assays and with the ability to measure distinct subsets in heterogeneous populations, flow cytometry is ideally suited to RO measurements. This article highlights the importance of RO assays on the flow cytometric platform in the development of biotherapeutic agents.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Descubrimiento de Drogas / Citometría de Flujo / Anticuerpos Tipo de estudio: Prognostic_studies / Qualitative_research Límite: Humans Idioma: En Revista: Cytometry B Clin Cytom Año: 2016 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Descubrimiento de Drogas / Citometría de Flujo / Anticuerpos Tipo de estudio: Prognostic_studies / Qualitative_research Límite: Humans Idioma: En Revista: Cytometry B Clin Cytom Año: 2016 Tipo del documento: Article